Biotechnology company Frontera Therapeutics has raised $160 million in series B fundraising.
According to a July 19 Frontera Therapeutics press release provided to Becker's, Frontera Therapeutics specializes in creating gene therapy candidates for various diseases. In addition to the fundraising announcement, Frontera Therapeutics confirmed that the FDA accepted the company's application to begin human clinical trials for their gene therapy drug designed to treat rare genetic retinal disease.
The financing will create new manufacturing capabilities and investment in clinical development.